Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER plus or to ER- disease?

被引：1
|
作者：
Landmann, Alessandra
Farrugia, Daniel J.
Diego, Emilia
Soran, Atilla
Johnson, Ronald
Bonaventura, Marguerite
Dabbs, David J.
Clark, Beth
Brufsky, Adam
Davidson, Nancy E.
Lembersky, Barry C.
Jankowitz, Rachel Catherine
Puhalla, Shannon
Ahrendt, Gretchen M.
McAuliffe, Priscilla F.
Bhargava, Rohit
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] UPMC, Magee Womens Hosp, Pittsburgh, PA USA
[4] Magee Womens Hosp, Pittsburgh, PA USA
[5] Magee Womens Hosp, Dept Path, Pittsburgh, PA USA
[6] NRG Oncol NSABP, Pittsburgh, PA USA
[7] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells
    Jonsson, Philip
    Katchy, Anne
    Williams, Cecilia
    ENDOCRINE-RELATED CANCER, 2014, 21 (02) : 143 - 160
  • [42] Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER plus ) breast cancer by IHC4 or Ki67 alone
    Sheri, A.
    Smith, I. E.
    A'Hern, R.
    Jones, R.
    Parton, M.
    Johnston, S. R. D.
    Dowsett, M.
    CANCER RESEARCH, 2013, 73
  • [43] Adenoid cystic carcinomas of the breast express ER-α36, a novel variant of human estrogen receptor-α (ER-α166)
    Gatalica, Z.
    Deng, H.
    Grazio, S.
    Lamovec, J.
    Palozzo, J.
    Wang, Z. Y.
    LABORATORY INVESTIGATION, 2008, 88 : 31A - 31A
  • [44] Elucidating the Mechanism of Action of Lenvatinib in Estrogen Receptor-Positive (ER plus ) Breast Cancer
    Gandasasmita, Natasha
    Vaidya, Gauri
    Datta, Arpita
    Marvalim, Charlie
    Lim, Joline Si Jing
    Lee, Soo Chin
    CANCER RESEARCH, 2024, 84 (08)
  • [45] Neoadjuvant endocrine therapy for estrogen receptor (ER) positive breast cancer: Comprehensive systematic review and meta-analysis
    Spring, L.
    Gupta, A.
    Reynolds, K. L.
    Gadd, M. A.
    Isakoff, S. J.
    Ellisen, L. W.
    Moy, B.
    Bardia, A.
    CANCER RESEARCH, 2016, 76
  • [46] Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER plus ) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial
    Wapnir, Irene
    Price, Karen N.
    Anderson, Stewart J.
    Robidoux, Andre
    Nortier, Miguel Martin J. W. R.
    Paterson, Alexander H. G.
    Rimawi, Mothaffar F.
    Lang, Istvan
    Canada, Jose Manuel Baena
    Thurlimann, Beat J. K.
    Mamounas, Eleftherios P.
    Geyer, Charles E.
    Gelber, Shari I.
    Coates, Alan S.
    Gelber, Richard D.
    Rastogi, Priya
    Regan, Meredith M.
    Wolmark, Norman
    Aebi, Stefan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells
    Zhang, XinTian
    Deng, Hao
    Wang, Zhao-Yi
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014, 143 : 434 - 443
  • [48] Differential pathway activation by OSM regulates bone dissemination in ER plus and ER- breast cancer
    Omokehinde, Tolu
    Jotte, Alec
    Johnson, Rachelle
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 14 - 15
  • [49] Adenoid cystic carcinomas of the breast express ER-α36, a novel variant of human estrogen receptor-α (ER-α66)
    Gatalica, Z.
    Deng, H.
    Grazio, S.
    Lamovec, J.
    Palazzo, J.
    Wang, Z. Y.
    MODERN PATHOLOGY, 2008, 21 : 31A - 31A
  • [50] The shared genetic landscape of polycystic ovary syndrome and breast cancer: convergence on ER plus breast cancer but not ER- breast cancer
    Bi, Kaixin
    Chen, Miaoran
    Zhao, Qianru
    Yang, Tongtong
    Xie, Wenjia
    Ma, Wenqi
    Jia, Hongyan
    BREAST CANCER RESEARCH, 2024, 26 (01)
12345